1832 Asset Management’s iBio IBIO Stock Holding History

1832 Asset Management’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-30	Closed	-$30K	–	723
2020 Q3	$30K	Buy	+30	New	+$43.5K	﹤0.01%	610

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

1832 Asset Management's IBIO Position: Q4 2020 in Review

1832 Asset Management sold out of iBio (IBIO) in Q4 2020, closing a stake of 30 shares — an estimated $30K sold.

1832 Asset Management first reported a position in IBIO in Q3 2020 and held it in 1 quarter. The position peaked at $30K in Q3 2020. 89 funds tracked by Wall St. Rank hold IBIO as of Q4 2020.

1832 Asset Management reported no remaining iBio position as of Q4 2020 after selling out during the quarter.
1832 Asset Management sold 30 iBio shares in Q4 2020, an estimated $30K.
1832 Asset Management first reported a position in iBio in Q3 2020 and held it in 1 quarter.
1832 Asset Management's iBio position peaked at $30K in Q3 2020.
89 funds tracked by Wall St. Rank held iBio as of Q4 2020.

Based on 1832 Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.